Antiva Biosciences, a South San Francisco, CA-based biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, raised $22m in Series C funding.
The round was led by Brace Pharma Capital with participation from new investors NS Investment, Osage University Partners and Alexandria Venture Investments and existing investors Canaan Partners and Sofinnova Ventures. In conjunction with the funding, Brace Pharma Capital President and CEO Vinzenz Ploerer has joined Antiva’s board of directors.
The company intends to use the funds to advance its ABI-1968 into clinical studies.
Founded in 2012 by Dr. Karl Hostetler of The University of California San Diego and led by Gail Maderis, president and CEO, Antiva develops novel, topical therapeutics for the treatment of diseases caused by HPV infection.
Last week, the company initiated a Phase 1 clinical study of its lead compound, ABI-1968, which will assess tolerability and safety of this topical therapy when administered intravaginally to healthy women. Antiva plans to commence a Phase 1b clinical study in patients with high grade cervical intraepithelial neoplasia (CIN 2,3) later this year. CIN is a precancerous condition caused by HPV in which abnormal cell growth occurs on the surface of the cervix.